Sintilimab is indicated for: (1) use in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in patients with negative EGFR mutations and ALK negativity who have not received prior systemic therapy; (2) use in combination with gemcitabine and platinum-based chemotherapy for the first-line treatment of unresectable advanced or recurrent squamous NSCLC. Additionally, sintilimab has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of T-cell lymphoma.